Table 3:
KRAS
and sensitivity to anti-EGFR agents in phase III trial.
Trial
Anti-EGFR agent
Total number of patients
(
𝑛
)
Patients tested for
KRAS
(
𝑛
)
KRAS mutant
𝑛
(%)
Survival in KRAS mutant (HR)
TRIBUTE [
46
]
Gefitinib
1079
264
55 (21)
2.1*
BR. 21 [
47
]
Erlotinib
731
206
30 (15)
1.67
SATURN [
48
]
Erlotinib
889
493
90 (18)
0.79
ATLAS [
15
]
Erlotinib
768
NR
NR
0.92
INTEREST [
49
]
Gefitinib
1466
275
49 (18)
0.91
FLEX [
57
]
Cetuximab
1125
379
72 (19)
1.0
BMS099 [
56
]
Cetuximab
676
202
35 (17)
0.95
HR: hazard ratio; NR: not reported. *Statistically significant.